Liquidia (LQDA) to Release Earnings on Wednesday

Liquidia (NASDAQ:LQDA) is set to post its quarterly earnings results before the market opens on Wednesday, November 13th. Analysts expect Liquidia to post earnings of ($0.37) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Liquidia Stock Down 2.7 %

LQDA stock opened at $10.73 on Tuesday. Liquidia has a 52 week low of $6.10 and a 52 week high of $16.99. The firm has a market capitalization of $823.96 million, a P/E ratio of -6.83 and a beta of 0.21. The company has a fifty day simple moving average of $10.40 and a two-hundred day simple moving average of $11.55.

Insider Buying and Selling

In other Liquidia news, insider Rajeev Saggar sold 2,526 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $11.19, for a total value of $28,265.94. Following the completion of the sale, the insider now directly owns 204,857 shares of the company’s stock, valued at $2,292,349.83. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Caligan Partners Lp purchased 150,000 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were purchased at an average price of $9.51 per share, for a total transaction of $1,426,500.00. Following the completion of the purchase, the director now owns 6,994,997 shares in the company, valued at approximately $66,522,421.47. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Rajeev Saggar sold 2,526 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $11.19, for a total transaction of $28,265.94. Following the completion of the sale, the insider now directly owns 204,857 shares of the company’s stock, valued at approximately $2,292,349.83. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,551 shares of company stock valued at $236,021 in the last 90 days. Company insiders own 30.10% of the company’s stock.

Wall Street Analysts Forecast Growth

LQDA has been the topic of several analyst reports. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. Bank of America cut their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Scotiabank began coverage on Liquidia in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target on the stock. HC Wainwright dropped their price objective on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $25.00 price objective on shares of Liquidia in a research report on Monday, August 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.67.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).